Alberta Research Council Incorporated

Other

Robert M Ippolito

Richard H Smith

Om P Srivastava

Wasimul Haque

Andre P Venot

Mohammed A Kashem

Roman Szweda

Pandurang V Nikrad

Ulrike Spohr

H Rizk Hanna

Cong Jiang

John Donald Payzant

James Kenneth Laidler

Stephen Vigmond

Individual sweet glycosides are obtained from the stevia rebaudiana plant. A mixture of sweet glycosides extracted from the stevia rebaudiana plant are processed to remove impurities by using two ion exchange columns. After removing the mixed sweet glycosides from the second column with methanol the solution is dried. Upon refluxing the dried solids in a methanol solution and then cooling the solution, Stevioside precipitates out. The filtrate is further concentrated and cooled to precipitate out Rebaudioside A. This Rebaudioside A can be further purified as can the previously obtained Stevioside.

Method of extracting selected sweet glycosides from the Stevia

The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.

Administration of valienamine-related disaccharide compounds in reducing

Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammals. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type II core structure wherein the administration of such oligosaccharide glycosides is after initiation of the mammal's immune response but at or prior one-half the period of time required to effect maximal antigen-induced inflammation.

Time dependent administration of oligosaccharide glycosides related to

Disclosed are novel Lewis.sup.x and Lewis.sup.a analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.

Immunosuppressive and tolerogenic modified Lewis.sup.x compounds

There is described a novel process for preparing 4-pyridinylmethyl ketones of formula (I) ##STR1## wherein R is alkyl, aryl or aralkyl. The process involves hydrolysis of a compound ##STR2## generated by reaction of an acylating agent with 4-methylpyridine. The acylating agent may be selected from compounds of formula R-CO-X and R-CO-O-CO-R where R is as defined above and X represents halogen. Compounds of formula I have utility in the preparation of a variety of products, including pharmaceutically active 1,2-dihydro-6-R-2-oxo-5 pyridinyl compounds.

Process for preparing certain 1-lower alkanoyl or benzoyl-4-(lower

Growing community of inventors

Edmonton, Canada

Robert M Ippolito